Go online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't miss this opportunity to learn why these customizable and convenient agents are part of the revolution in care for MM. Upon completion of this activity, participants should be better able to: State the rationale for and current evidence supporting the use of BCMA-targeting options in RRMM, including triple-class–refractory disease; Create sequential, evidence-based treatment plans that integrate novel antibody options for management of patients with RRMM; Utilize proven tools and cross-disciplinary teamwork to manage the unique safety considerations associated with BCMA-directed antibodies, including ocular toxicity, CRS, and neurotoxicity, among others